Mechanisms of cell injury and death in cholestasis and hepatoprotection by ursodeoxycholic acid

Journal of Hepatology, Supplement

Volumn 32, Issue 2, 2000, Pages 11-13

  Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL SURFACE RECEPTOR; CYTOCHROME C OXIDASE; URSODEOXYCHOLIC ACID;

APOPTOSIS; CELL DAMAGE; CHOLESTASIS; CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; LIVER DISEASE; LIVER PROTECTION; PRIORITY JOURNAL;

EID: 0034017203     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80435-3     Document Type: Conference Paper

References (16)

1. Patel T, Roberts LR, Jones BA, Gores GJ. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998; 18: 105-14.
2. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-6.
3. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-6.
4. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-8.
5. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-91.
6. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997; 26: 1399-405.
7. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999; 117: 669-77.
8. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137-45.
9. Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Mcd 1994; 121: 207-18.
10. Poupon RE, Poupon R, Baikau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994; 330: 1342-7.
11. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104: 1865-70.
12. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; ll: 12-5.
13. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995; 272: 930-8.
14. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
15. Que FG, Phan VA, Phan VH, LaRusso NF, Gores GJ. GUDC inhibits cytochrome C release from human cholangiocyte mitochondria. J Surg Res 1999; 83: 100-5.
16. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome C release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Diff 1999; 6: 842-54.